SCHEMBL5446288

SCHEMBL5446288

NC(=O)c1c(NC(=O)Nc2ccc(F)c(Cl)c2)sc2c1CCCC2

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.59
MEN1 O00255 4/20 0.59
KMT2A Q03164 4/20 0.59
ALDH1A1 P00352 3/20 0.59
GAA P10253 2/20 0.59
NPC1 O15118 6/20 0.59
RAB9A P51151 6/20 0.59
FLT3 P36888 7/20 0.57
LMNA P02545 2/20 0.57
CFTR P13569 1/20 0.57
KDM4E B2RXH2 1/20 0.57
USP2 O75604 1/20 0.57
HTT P42858 1/20 0.57
ATM Q13315 1/20 0.57
KCNH2 Q12809 2/20 0.55
CYP1A2 P05177 1/20 0.53
CYP2C19 P33261 1/20 0.53
SMN1; SMN2 Q16637 2/20 0.52
SLC2A1 P11166 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460074 0.91 MEN1 (0.67) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL8289550 0.90 MEN1 (0.62) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL5453522 0.86 MEN1 (0.55) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL4234573 0.86 FLT3 (0.72) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL5453060 0.85 CFTR (0.54) MAPTMEN1KMT2AALDH1A1NPC1
SCHEMBL5453304 0.85 KDR (0.57) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL5455065 0.85 MEN1 (0.79) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL5446174 0.84 FLT3 (0.71) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL5455531 0.84 FLT3 (0.61) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL18015730 0.84 KCNH2 (0.71) MAPTMEN1KMT2AALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 MAPT 21/4885MEN1 2891/4885KMT2A 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.